User profiles for "author:Peter Jüni"
 | Peter JüniProfessor of Medicine and Clinical Trials, University of Oxford Verified email at ndph.ox.ac.uk Cited by 263602 |
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …
F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the …
A Vahanian, F Beyersdorf, F Praz… - European heart …, 2022 - academic.oup.com
Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …
when exercising their clinical judgment, as well as in the determination and the …
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
C Stettler, S Wandel, S Allemann, A Kastrati… - The Lancet, 2007 - thelancet.com
Background Whether the two drug-eluting stents approved by the US Food and Drug
Administration—a sirolimus-eluting stent and a paclitaxel-eluting stent—are associated with …
Administration—a sirolimus-eluting stent and a paclitaxel-eluting stent—are associated with …
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Flaws in the design, conduct, analysis, and reporting of randomised trials can cause the
effect of an intervention to be underestimated or overestimated. The Cochrane …
effect of an intervention to be underestimated or overestimated. The Cochrane …
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Non-randomised studies of the effects of interventions are critical to many areas of
healthcare evaluation, but their results may be biased. It is therefore important to understand …
healthcare evaluation, but their results may be biased. It is therefore important to understand …
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the …
comprehensive review of the published evidence for management of a given condition
according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of …
according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of …
Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis
Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …
[HTML][HTML] Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease
B De Bruyne, NHJ Pijls, B Kalesan… - … England Journal of …, 2012 - Mass Medical Soc
Background The preferred initial treatment for patients with stable coronary artery disease is
the best available medical therapy. We hypothesized that in patients with functionally …
the best available medical therapy. We hypothesized that in patients with functionally …
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
J Daemen, P Wenaweser, K Tsuchida, L Abrecht… - The Lancet, 2007 - thelancet.com
Background Stent thrombosis is a safety concern associated with use of drug-eluting stents.
Little is known about occurrence of stent thrombosis more than 1 year after implantation of …
Little is known about occurrence of stent thrombosis more than 1 year after implantation of …
RoB 2: a revised tool for assessing risk of bias in randomised trials
Assessment of risk of bias is regarded as an essential component of a systematic review on
the effects of an intervention. The most commonly used tool for randomised trials is the …
the effects of an intervention. The most commonly used tool for randomised trials is the …